食品伙伴網(wǎng)訊 2022年3月30日,據(jù)歐盟食品安全局(EFSA)消息,歐盟營養(yǎng)、新型食品和食物過敏原(NDA)研究小組就延長使用低聚半乳糖(galacto-oligosaccharides)作為新型食品用于特殊醫(yī)學(xué)用途食品中的安全性發(fā)表科學(xué)意見。
經(jīng)過評(píng)估,專家小組得出結(jié)論,在建議的使用條件下,延長低聚半乳糖在特殊醫(yī)學(xué)用途食品中的使用是安全的。部分原文報(bào)道如下:
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the extension of use of galacto-oligosaccharides (GOS) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF (β-GOS) is produced from milk lactose using a β-galactosidase derived from Bifidobacterium bifidum and it is proposed to be used in food for special medical purposes (FSMP). The target population is the general population from 4 years of age onwards. GOS produced according to the same production process are already authorised and included in the EU Union list of novel foods. The applicant stated that the maximum daily intake from the use in FSMP is 8.25 g GOS. GOS are already authorised for use in food supplements up to a daily dose of 16.2 g. FSMP containing GOS are not intended to be used if food supplements containing GOS are consumed on the same day. The information provided on the proposed use levels and anticipated intake does not raise safety concerns. The Panel concludes that the proposed extension of use of GOS in FSMP is safe under the proposed conditions of use.
本文由食品伙伴網(wǎng)食品資訊中心編輯,供網(wǎng)友參考,有任何疑問,請(qǐng)聯(lián)系news@foodmate.net。